Back to Results
First PageMeta Content
Piperazines / Clinical pharmacology / Food and Drug Administration / Therapeutics / United States Public Health Service / European Medicines Agency / Biosimilar / Food and Drug Administration Amendments Act / Moxifloxacin / Pharmacology / Pharmaceutical sciences / Clinical research


FDA Briefing Document Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) November 4, 2013 DISCLAIMER STATEMENT
Add to Reading List

Open Document

File Size: 63,83 KB

Share Result on Facebook

Company

Best Pharmaceuticals / /

Event

FDA Phase / /

IndustryTerm

oncology products / investigational therapeutic oncology products / biological products / oncology product / products / therapies for pediatric rare diseases / investigational oncology products / pediatric age / biologic products / /

MedicalCondition

specific pediatric cancer / rare diseases / cancer / tumors / disease / adult cancer / original rare disease / rare disease / childhood cancer / sleeplessness / rare pediatric disease / entire disease / pain / select pediatric cancer / Therefore pediatric tumors / fatigue / specific cancer / cough / pediatric rare disease / depression / pediatric rare diseases / respiratory distress / /

Movie

Quality of life / /

Organization

Congress / Oncology Subcommittee / office of Hematology and Oncology Products / Food and Drug Administration / European Medicines Agency / Review Committee / Review Division / Children and Adolescents Task Force / DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring / Oncologic Drugs Advisory Committee / FDA Briefing Document Pediatric Oncology Subcommittee / International Society for Pharmacoeconomics and Outcomes Research / Advisory Committee / Pediatric Oncology Subcommittee / /

Person

Richard Pazdur / /

Position

Director / /

Product

Act / /

ProvinceOrState

Maryland / /

Technology

drug development / /

URL

http /

SocialTag